Clinical trial
A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study
NCT00454168 is registered in ClinicalTrials.gov with The Vaccine Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-Blind, Multicenter Study of Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF in Elderly Patients With AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study
- Lead sponsor
- The Vaccine Company
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- May 31, 2005
- Completion date
- Not reported
- Enrollment
- 244 (estimated)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.